Evidence map›Paper›PMID 41591419›Full record

ReviewDermatologie (Heidelberg, Germany)2026

[Botulinum toxin preparations in dermatology : Characterization, comparison, and treatment options].

Seher Eren, Alina Fratila, Klaus Fritz, Carmen Maria Salavastru

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Dermatologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Seher ErenHautärzte am Marktplatz, Kaiserstr. 72, 76133, Karlsruhe, Deutschland. contact@drsehereren.com.
Alina FratilaJungbrunnen-Klinik GmbH, Bonn, Deutschland.
Klaus FritzHautärzte und Laserzentrum, Landau (Pfalz), Deutschland.
Carmen Maria SalavastruColentina Krankenhaus, Abt. Pädiatrische Dermatologie, Dermatoonkologische Forschungseinrichtung, Carol Davila Universität für Medizin und Pharmazie, Bukarest, Rumänien.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Botulinum toxin type A (BTX-A) is an established component of dermatological practice and is primarily used for the treatment of facial expression lines as well as axillary hyperhidrosis, and also for off-label dermatological conditions. Worldwide, BTX‑A preparations are available that differ in composition, activity, dosage, and approved indications. An identical BTX‑A active substance may be marketed under different brand names with a similar formulation but different approved indications.

Indexed as

Axillary hyperhidrosisForehead linesGlabellar linesLateral canthal linesProduct-specific potency units

Identifiers

PMID41591419

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.